• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Entera Bio Ltd. - Ordinary Shares (NQ:ENTX)

    3.140 +0.150 (+5.02%)
    Delayed Quote Updated: 4:00 PM EST, Nov 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 118,328
    Open 3.030
    Bid (Size) 2.900 (800)
    Ask (Size) 3.290 (3,000)
    Prev. Close 2.990
    Today's Range 2.910 - 3.180
    52wk Range 0.9100 - 4.200
    Shares Outstanding 28,804,411
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Entera Announces Third Quarter 2026 Financial Results and Business Updates
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
    From Entera Bio Ltd.
    Via GlobeNewswire

    Performance

    52-Week Range 25.2% below 52-week high
    3.140
    0.9152W Low 4.2052W High
    1 Week 4.6% below 1-week high
    2.901W Low 3.291W High

    Entera Bio Ltd. - Ordinary Shares (ENTX) traded between $0.91 and $4.20 over the past 52 weeks and last traded at $3.14, 25.2% below its 52-week high. Over the past week it ranged between $2.90 and $3.29.

    Past 12 Months
    +1.6%
    +25.6%
    +3.3%
    +168.4%
    +77.4%
    N/A
    1W +$0.05
    1M +$0.64
    3M +$0.10
    6M +$1.97
    YTD +$1.37
    1Y  

    ENTX was +168.4% over six months, +77.4% year to date, +1.6% in the last week.

    12 Months vs Market
    ENTX
    N/A
    DIA
    +9.0%
    SPY
    +9.6%
    QQQ
    +7.6%
    IWM
    +13.3%

    Over the past 12 months ENTX returned N/A versus DIA (Dow) +9.0%, SPY (S&P 500) +9.6%, QQQ (Nasdaq 100) +7.6% and IWM (Russell 2000) +13.3%.

    Volume & Liquidity 0.25× 3-mo avg
    Today 118,328 3-mo avg 464.8K
    1W
    219.2K
    1M
    519.7K
    3M
    464.8K
    6M
    1.5M
    YTD
    962.2K
    1Y
    836.7K

    ENTX most recently traded 118,328 shares against a 3-month average daily volume of 464.8K.

    More News

    Read More
    News headline image
    Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
    From Entera Bio Ltd.
    Via GlobeNewswire
    These stocks are moving in today's pre-market session ↗
    Via Chartmill
    News headline image
    Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
    From Entera Bio Ltd.
    Via GlobeNewswire
    Entera Bio (NASDAQ:ENTX) Slides on Wider Q2 Loss Despite FDA Phase 3 Alignment and $275M Cash Raise ↗
    Via Chartmill
    News headline image
    Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    Correction: Entera to Participate in Upcoming Fall Investor Conferences
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    Entera to Participate in Upcoming Fall Investor Conferences
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    Entera Bio Eyes Phase 3 Start for Oral Osteoporosis Drug EB613 After FDA Agreement ↗
    Via MarketBeat
    News headline image
    Entera Announces Second Quarter 2026 Financial Results and Business Updates
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
    From Entera Bio Ltd.
    Via GlobeNewswire
    Which stocks are moving on Monday? ↗
    Via Chartmill
    Curious about the most active stocks on Monday? ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
    Via Benzinga
    Monday's session: top gainers and losers ↗
    Via Chartmill
    Let's uncover which stocks are experiencing notable gaps during today's session. ↗
    Via Chartmill
    News headline image
    Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
    From Entera Bio Ltd.
    Via GlobeNewswire
    What's going on in today's after hours session ↗
    Via Chartmill
    Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗
    Via Chartmill
    News headline image
    Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
    From Entera Bio Ltd.
    Via GlobeNewswire
    News headline image
    ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
    From Entera Bio Ltd.
    Via GlobeNewswire

    Frequently Asked Questions

    Is Entera Bio Ltd. - Ordinary Shares publicly traded?
    Yes, Entera Bio Ltd. - Ordinary Shares is publicly traded.
    What exchange does Entera Bio Ltd. - Ordinary Shares trade on?
    Entera Bio Ltd. - Ordinary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Entera Bio Ltd. - Ordinary Shares?
    The ticker symbol for Entera Bio Ltd. - Ordinary Shares is ENTX on the Nasdaq Stock Market
    What is the current price of Entera Bio Ltd. - Ordinary Shares?
    The current price of Entera Bio Ltd. - Ordinary Shares is 3.140
    When was Entera Bio Ltd. - Ordinary Shares last traded?
    The last trade of Entera Bio Ltd. - Ordinary Shares was at 11/06/26 04:00 PM ET
    What is the market capitalization of Entera Bio Ltd. - Ordinary Shares?
    The market capitalization of Entera Bio Ltd. - Ordinary Shares is 90.45M
    How many shares of Entera Bio Ltd. - Ordinary Shares are outstanding?
    Entera Bio Ltd. - Ordinary Shares has 90M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.